

Clinical management of combined TB and diabetes

Reinout van Crevel

*Radboud University Medical Centre,
Nijmegen, The Netherlands*



How to find TB-DM patients?

WP1

Bidirectional screening:
- prevalence in 4 countries
- tools and algorithms
- health economic aspects

How to manage TB-DM patients?

WP2

DM management during TB treatment
Health economics
TB outcome
DM treatment needs after TB treatment

What is the cellular / molecular basis of TB susceptibility in DM?

WP4

In-vitro studies: macrophages, adipocytes
Patient genetic studies
Functional Genomics (linking genetics & in-vitro)

What explains poor TB outcome in DM?

WP3

Bioprofiles in TB, DM and TB-DM:
gene expression; proteomics / metabolomics; leukocyte phenotyping
Effect hyperglycemia / TB treatment




Clinical management of TB-DM

1. Should we adjust TB treatment in dose or duration?
2. Glycemic control: how important is it for TB?
3. Should we use insulin or metformin?
4. Is there more toxicity in TB-DM? should we monitor a TB-DM patient more intensively?
5. Can we explain the higher mortality in TB-DM? What other treatments should we consider?
6. What about lifestyle and smoking?
7. How to adjust counseling & education?
8. Where should patients be treated, how to coordinate care?
9. How to continue DM care after TB treatment?
10. ..

Longer duration TB treatment?

- Taiwan, insurance database, 12688 TB-DM, 43195 TB
- two-year TB recurrence rate: **2.20%** TB DM vs 1.38% TB ($p < 0.001$)
- 9 versus 6 months anti-TB treatment
 - lower recurrence rate in DM (**HR 0.76** [0.59-0.97]),
 - under conditions of full DOTs (**HR 0.69** [0.43-1.11]).




- higher dose?
(~ body weight or per kg)


Wang, J. Y. et al, CHEST 2014

Glycemic control in TB-DM


- Range in dysglycemia
- How much is due to inflammation?
- Will it affect TB outcomes?
- When/ how should we aim for glycemic control?



TANDEM
(unpublished)




Glycemic control is difficult in TB-DM



*Clinical Management of concurrent TB and DM and the implications for patient services.
Riza et al, Lancet Diabetes 2014;2:740-53*

Constraints and challenges in access to insulin: a global perspective

David Beran, Margaret Ewen, Richard Laing



Beran et al. Lancet Diabetes 2016;4:275-285

Should we use insulin or metformin?

Insulin:

- No drug interaction
- More effective than oral

But:

- Need for self-monitoring
- Risk of hypoglycemia
- Access & availability
- Prescribed by TB doctors?
- Accepted by TB patients?

metformin:

- No drug interaction?
- No risk of hypoglycemia
- Widely available

But:

- Side effects
- Use in kidney dysfunction
- Safety?

How hard should we aim for glycemic control?


Pragmatic clinical trial in TANDEM

- Standard versus intensified management
- Intervention: counseling, more frequent measurement, adjustment of DM medication according to simple algorithms
- Frequent encounters with TB providers good opportunity for counseling, including lifestyle (smoking!)



DM care often substandard

- in 'the South' or those at highest TB risk in 'the North'
- access
- retention
- glycemic control
- insufficient primary / secondary prevention cardiovascular disease



increased (early) mortality of TB-DM

Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania

Daniel Faurholt-Jepsen¹, Nyagosya Range², George PrayGod³, Kidola Jeremiah³, Maria Faurholt-Jepsen¹, Martine G. Aabye⁴, John Changalucha³, Dirk L. Christensen⁵, Harleen M. S. Grewal⁶, Torben Martinussen⁷, Henrik Krarup⁸, Daniel R. Witte⁹, Aase B. Andersen¹⁰ and Henrik Friis¹

Trop Med
Int Health '13

- 1250 pts, 51% HIV+, 17% DM
- death < 3 mths: RR 5.0 in HIV/DM; RR 2.2 in DM

Impact of Diabetes and Smoking on Mortality in Tuberculosis

George W. Reed¹, Hongjo Choi², So Young Lee², Myungsun Lee², Youngran Kim², Hyemi Park², Jongseok Lee², Xin Zhan⁴, Hyeungseok Kang⁵, SooHee Hwang⁵, Matthew Carroll⁶, Ying Cai⁶, Sang-Nae Cho^{2,3}, Clifton E. Barry III⁶, Laura E. Via⁶, Hardy Kornfeld^{7*}

Plos One '13

- Taiwan, 657 pts, 20% DM, 80% smoking (HIV+ excluded)
- 1-year mortality 6% in non-DM, 13% in DM
- DM plus smoking: one-year TB-ass mortality: HR 5.78

Clinicaltrials.gov

18 studies found for: **Diabetes AND tuberculosis**

[Modify this search](#) | [How to Use Search Results](#)

List

By Topic

On Map

Search Details

+ Show Display Options

 Download

 Subscribe to RSS

Include only open studies Exclude studies with Unknown status

Rank	Status	Study
1	Recruiting	<p>Pulmonary Tuberculosis Patients With Diabetes Mellitus</p> <p>Conditions: Diabetes Mellitus; Pulmonary Tuberculosis</p> <p>Intervention: Procedure: intensive monitoring</p>
2	Not yet recruiting	<p>Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis</p> <p>Conditions: Type 2 Diabetes Mellitus; Pulmonary Tuberculosis</p> <p>Interventions: Dietary Supplement: Vitamin D; Dietary Supplement: Calcium; Dietary Supplement: Placebo Vit D; Dietary Supplement: Placebo Calcium</p>
3	Terminated	<p>Immunobiology of Diabetes and Tuberculosis</p> <p>Conditions: Tuberculosis; Diabetes Mellitus</p> <p>Intervention: Biological: BCG</p>
4	Completed	<p>Nutrition, Diabetes and Pulmonary TB/HIV</p> <p>Conditions: Tuberculosis; HIV; Diabetes</p> <p>Interventions: Dietary Supplement: Multimicronutrients; Dietary Supplement: Energy and proteins</p>
5	Active, not recruiting	<p>Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment</p> <p>Condition: Diabetes Mellitus, Type 2</p>

Tuberculosis and HIV

315 studies found for: HIV AND tuberculosis
[Modify this search](#) | [How to Use Search Results](#)

List

By Topic

On Map

Search Details

+ Show Display Options

 Download

 Subscribe to RSS

Include only open studies Exclude studies with Unknown status

Rank	Status	Study
1	Recruiting	Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Conditions: Influenza; HIV; Tuberculosis Intervention: Biological: Trivalent Inactivated Influenza Vaccine
2	Completed Has Results	Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST) Conditions: HIV; Tuberculosis Intervention: Drug: Fixed dose combination zidovudine/lamivudine/abacavir
3	Unknown †	Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection Conditions: Latent Tuberculosis Infection; HIV Infections; Tuberculosis Intervention:
4	Terminated Has Results	Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV Conditions: HIV Infection; Tuberculosis; Pneumocystis Jiroveci Pneumonia Interventions: Drug: Isoniazid (INH); Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX); Drug: Isoniazid Placebo (PL)

Clinical management of TB-DM

- TB treatment: longer? Higher dose rifampicin?
- Glycemic control: how important is it for TB?
- Should we use insulin or metformin?
- Is there more toxicity in TB-DM? should we monitor a TB-DM patient more intensively?
- Can we explain the higher mortality in TB-DM? What other treatments should we consider?

- Need for studies 'beyond screening' for TB-DM
- including (pragmatic) clinical trials